GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Cash Conversion Cycle

MURA (Mural Oncology) Cash Conversion Cycle : 0.00 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Mural Oncology's Days Sales Outstanding for the three months ended in Sep. 2024 was .
Mural Oncology's Days Inventory for the three months ended in Sep. 2024 was .
Mural Oncology's Days Payable for the three months ended in Sep. 2024 was .
Therefore, Mural Oncology's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2024 was 0.00.


Mural Oncology Cash Conversion Cycle Historical Data

The historical data trend for Mural Oncology's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Cash Conversion Cycle Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Cash Conversion Cycle
- - -

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mural Oncology's Cash Conversion Cycle

For the Biotechnology subindustry, Mural Oncology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Cash Conversion Cycle falls into.



Mural Oncology Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Mural Oncology's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Mural Oncology's Cash Conversion Cycle for the quarter that ended in Sep. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Mural Oncology Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology Business Description

Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.